{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"15.1","value":"9.3"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"18.5","value":"12.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Each regimen was monitored for excessive acute toxicity (defined as nonhematologic grade 4 toxicity within 90 days of the start of radiation or any grade 5 toxicity). The target rate was based on the observed rate from RTOG-9501/NCT00002670 of 15%. The unacceptable rate was \\>30%. \\[RTOG = Radiation Therapy Oncology Group\\]","dispersionType":"95% Confidence Interval","groups":[{"description":"Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.","id":"OG000","title":"RT+Cisplatin+Cetuximab"},{"description":"Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.","id":"OG001","title":"RT+Docetaxel+Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started protocol treatment and did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From start of treatment to last follow-up. Analysis occurs at the time of the primary analysis.","title":"Frequency of Toxicity (Grade 5 and Acute Non-hematologic Grade 4)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}